We identify the Hippo pathway as a potential therapeutic target in systemic sclerosis, and describe its role in both myofibroblast and EndoMT transition, two key cellular events in SSc pathogenesis, and provide a link with the sex-biased Hippo pathway regulator VGLL3. The gene discussed is VGLL3; the disease is systemic sclerosis.